<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-sub-section" /><meta name="keywords" content="ACE inhibitors: heart failure; ACE inhibitors: hypertension; Antihypertensives: ACE inhibitors; Angiotensin-converting enzyme inhibitors see ACE inhibitors; Heart failure: ACE inhibitors; Hypertension: ACE inhibitors; ACE inhibitors: renal function" /><meta name="IX" content="ACE inhibitors: heart failure; ACE inhibitors: hypertension; Antihypertensives: ACE inhibitors; Heart failure: ACE inhibitors; Hypertension: ACE inhibitors; ACE inhibitors: renal function" /><meta name="IXN" content="Angiotensin-converting enzyme inhibitors see ACE inhibitors" /><title>2.5.5.1 Angiotensin-converting enzyme inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2578.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2578.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2578.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2534.htm">2.5 Hypertension and heart failure</a> &gt; <a href="27510.htm">2.5.5 Drugs affecting the renin-angiotensin system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="119651.htm" title="Previous: Heart failure">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2579.htm" title="Next: CAPTOPRIL">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2578">2.5.5.1 Angiotensin-converting enzyme inhibitors</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i2.htm" title="Go to appendix 1">ACE Inhibitors</a>).</div><div><p>Angiotensin-converting enzyme
inhibitors (ACE inhibitors) inhibit the conversion of angiotensin
I to angiotensin II. They have many uses and are generally well tolerated.
The main indications of ACE inhibitors are shown below.</p><div id="_200328"><div class="cAZ"><h2>Heart failure</h2> <p class="cAX">ACE inhibitors are used in all grades of
heart failure, usually combined with a beta-blocker (<a title=" Drugs affecting the renin-angiotensin system" href="27510.htm#_27510">section 2.5.5</a>). Potassium
supplements and potassium-sparing diuretics should be discontinued
before introducing an ACE inhibitor because of the risk of hyperkalaemia.
However, a low dose of <span>spironolactone</span> may be beneficial
in severe heart failure (<a title=" Drugs affecting the renin-angiotensin system" href="27510.htm#_27510">section 2.5.5</a>) and
can be used with an ACE inhibitor provided serum potassium is monitored
carefully. Profound first-dose hypotension may occur when ACE inhibitors
are introduced to patients with heart failure who are already taking
a high dose of a loop diuretic (e.g. furosemide 80 mg daily or more).
Temporary withdrawal of the loop diuretic reduces the risk, but may
cause severe rebound pulmonary oedema. Therefore, for patients on
high doses of loop diuretics, the ACE inhibitor may need to be initiated
under specialist supervision, see below. An ACE inhibitor can be initiated
in the community in patients who are receiving a low dose of a diuretic
or who are not otherwise at risk of serious hypotension; nevertheless,
care is required and a very low dose of the ACE inhibitor is given
initially.</p></div></div><div id="_207477"><div class="cAZ"><h2>Hypertension</h2> <p class="cAX">An ACE inhibitor may be the most
appropriate initial drug for hypertension in younger Caucasian patients; Afro-Caribbean
patients, those aged over 55 years, and those with primary aldosteronism
respond less well (see <a title="section: Hypertension and heart failure" href="2534.htm#_2534">section 2.5</a>). ACE inhibitors are particularly
indicated for hypertension in patients with type 1 diabetes with nephropathy
(see also <a title=" Treatment of diabetic nephropathy and neuropathy" href="4201.htm#_4201">section 6.1.5</a>). They
may reduce blood pressure very rapidly in some patients particularly
in those receiving diuretic therapy (see Cautions, below); the first
dose should preferably be given at bedtime.</p></div></div><div class="cAZ"><h2>Diabetic nephropathy</h2> <p class="cAX">For comment on the role of
ACE inhibitors in the management of diabetic nephropathy, see <a title=" Treatment of diabetic nephropathy and neuropathy" href="4201.htm#_4201">section 6.1.5</a>.</p></div><div class="cAZ"><h2>Prophylaxis of cardiovascular events</h2> <p class="cAX">ACE inhibitors
are used in the early and long-term management of patients who have
had a myocardial infarction, see <a title=" Management of myocardial infarction" href="60552.htm#_60552">section 2.10.1</a>. ACE inhibitors may also have
a role in preventing cardiovascular events.</p></div><div id="_2578.7"><div class="cAZ"><h2>Initiation under specialist supervision</h2> <p class="cAX">ACE inhibitors
should be initiated under specialist supervision and with careful
clinical monitoring in those with severe heart failure or in those: </p><ul class="cBF"><li><p class="cQ">receiving multiple or high-dose diuretic therapy (e.g.
more than 80 mg of furosemide daily or its equivalent);</p></li><li><p class="cQ">with hypovolaemia;</p></li><li><p class="cQ">with hyponatraemia (plasma-sodium concentration below
130 mmol/litre);</p></li><li><p class="cQ">with hypotension (systolic blood pressure below 90 mmHg);</p></li><li><p class="cQ">with unstable heart failure;</p></li><li><p class="cQ">receiving high-dose vasodilator therapy;</p></li><li><p class="cQ">known renovascular disease.</p></li></ul></div></div><div id="_200330"><div class="cAZ"><h2>Renal effects</h2> <p class="cAX">Renal function and
electrolytes should be checked before starting ACE inhibitors (or
increasing the dose) and monitored during treatment (more
frequently if features mentioned below present); hyperkalaemia
and other side-effects of ACE inhibitors are more common in those
with impaired renal function and the dose may need to be reduced (see Renal impairment below and under individual drugs). Although
ACE inhibitors now have a specialised role in some forms of renal
disease, including chronic kidney disease, they also occasionally
cause impairment of renal function which may progress and become severe
in other circumstances (at particular risk are the elderly). A specialist should be involved if renal function is significantly
reduced as a result of treatment with an ACE inhibitor.</p><p>Concomitant treatment with NSAIDs increases the
risk of renal damage, and potassium-sparing diuretics
(or potassium-containing salt substitutes) increase the risk of hyperkalaemia.</p><p>In patients with severe bilateral renal artery stenosis (or severe
stenosis of the artery supplying a single functioning kidney), ACE
inhibitors reduce or abolish glomerular filtration and are likely
to cause severe and progressive renal failure. They are therefore
not recommended in patients known to have these forms of critical
renovascular disease.</p><p>ACE inhibitor treatment is unlikely to have an adverse effect
on overall renal function in patients with severe unilateral renal
artery stenosis and a normal contralateral kidney, but glomerular
filtration is likely to be reduced (or even abolished) in the affected
kidney and the long-term consequences are unknown. </p><p>ACE inhibitors are therefore best avoided in patients with known
or suspected renovascular disease, unless the blood pressure cannot
be controlled by other drugs. If ACE inhibitors are used, they should
be initiated only under specialist supervision and renal function
should be monitored regularly.</p><p>ACE inhibitors should also be used with particular caution in
patients who may have undiagnosed and clinically silent renovascular
disease. This includes patients with peripheral vascular disease or
those with severe generalised atherosclerosis.</p></div></div><div id="_200332"><div class="cAZ"><h2>Cautions</h2> <p class="cAX">ACE inhibitors need to be
initiated with care in patients receiving diuretics (<b>important:</b> see Concomitant diuretics, below); first doses can cause hypotension especially in patients
taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure (see above). They
should also be used with caution in peripheral vascular
disease or generalised atherosclerosis owing to risk of clinically silent renovascular disease; for use
in pre-existing renovascular disease, see <a title="target-block: ACE inhibitors renal effects" href="2578.htm#_200330">Renal Effects</a> above.
The risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended). ACE inhibitors should be used with care in patients with severe or symptomatic aortic stenosis
(risk of hypotension) and in hypertrophic
cardiomyopathy. They should also be used with care (or avoided) in those with a history
of idiopathic or hereditary angioedema. If jaundice or
marked elevations of hepatic enzymes occur during treatment then the
ACE inhibitor should be discontinued—risk of hepatic necrosis (see also Hepatic impairment, below). <b>Interactions:</b> Appendix 1 (ACE inhibitors).</p><div><h3 class="cAE">Anaphylactoid reactions</h3> <p class="cAE"><span id="_2578.9">To
prevent anaphylactoid reactions, ACE inhibitors should be avoided
during dialysis with high-flux polyacrylonitrile membranes and during
low-density lipoprotein apheresis with dextran sulphate; they should also be withheld before desensitisation
with wasp or bee venom</span>.</p></div><div style="margin-top: 1em"><h3 class="cAE">Concomitant diuretics</h3> <div id="_218762"><p>ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted
patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80 mg furosemide
or equivalent, the ACE inhibitor should be initiated under close supervision
and in some patients the diuretic dose may need to be reduced or the
diuretic discontinued at least 24 hours beforehand (may not be possible
in heart failure—risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation
is recommended after administration of the first dose of ACE inhibitor,
for at least 2 hours or until the blood pressure has stabilised.</p></div></div></div></div><div id="_200334"><div class="cAZ"><h2>Contra-indications</h2> <p class="cAX">ACE inhibitors are contra-indicated
in patients with hypersensitivity to ACE inhibitors (including
angioedema).</p></div></div><div id="_204159"><div class="cAZ"><h2>Hepatic impairment</h2> <p class="cAX">Use of prodrugs such as <span>cilazapril</span>, enalapril, <span>fosinopril</span>, imidapril,
moexipril, <span>perindopril</span>, <span>quinapril</span>, <span>ramipril</span>, and <span>trandolapril</span> requires close monitoring in patients with impaired liver function</p></div></div><div id="_204160"><div class="cAZ"><h2>Renal impairment</h2> <p class="cAX">ACE inhibitors should be used
with caution and the response monitored (see <a title="BNF:target-block: ACE inhibitors renal effects" href="2578.htm#_200330">Renal effects above</a>); hyperkalaemia and other side effects more common; the dose may
need to be reduced, see individual drugs.</p></div></div><div id="_204161"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">ACE inhibitors should be avoided in
pregnancy unless essential. They may adversely affect fetal and neonatal
blood pressure control and renal function; skull defects and oligohydramnios
have also been reported.</p></div></div><div id="_204162"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX"> Information on the use of ACE
inhibitors in breast-feeding is limited. Cilazapril, fosinopril, imidapril,
lisinopril, moexipril, perindopril, ramipril, and trandolapril are
not recommended; alternative treatment options, with better established
safety information during breast-feeding, are available. Captopril,
enalapril, and quinapril should be avoided in the first few weeks
after delivery, particularly in preterm infants, due to the risk of
profound neonatal hypotension; if essential, they may be used in mothers
breast-feeding older infants—the infant’s blood pressure should be
monitored.</p></div></div><div id="_200401"><div class="cAZ"><h2>Side-effects</h2> <p class="cAX">ACE inhibitors can cause profound
hypotension (see Cautions) and renal impairment (see Renal effects
above), and a persistent dry cough. They can also cause angioedema
(onset may be delayed; higher incidence reported in Afro-Caribbean
patients), rash (which may be associated with pruritus and urticaria),
pancreatitis, and upper respiratory-tract symptoms such as sinusitis,
rhinitis, and sore throat. Gastro-intestinal effects reported with
ACE inhibitors include nausea, vomiting, dyspepsia, diarrhoea, constipation,
and abdominal pain. Altered liver function tests, cholestatic jaundice,
hepatitis, fulminant hepatic necrosis, and hepatic failure have been
reported—discontinue if marked elevation of hepatic enzymes or jaundice.
Hyperkalaemia, hypoglycaemia, and blood disorders including thrombocytopenia,
leucopenia, neutropenia, and haemolytic anaemia have also been reported.
Other reported side-effects include headache, dizziness, fatigue,
malaise, taste disturbance, paraesthesia, bronchospasm, fever, serositis,
vasculitis, myalgia, arthralgia, positive antinuclear antibody, raised
erythrocyte sedimentation rate, eosinophilia, leucocytosis, and photosensitivity.</p></div></div><div class="cAZ"><h2>Combination products</h2> <p class="cAX">Products incorporating an
ACE inhibitor with a thiazide diuretic or a calcium-channel blocker
are available for the management of hypertension. Use of these combination
products should be reserved for patients whose blood pressure has
not responded adequately to a single antihypertensive drug and who
 have been stabilised on the individual components of the combination
in the same proportions.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2579"><a href="2579.htm" title="CAPTOPRIL">CAPTOPRIL</a></li><li id="_2583"><a href="2583.htm" title="CILAZAPRIL">CILAZAPRIL</a></li><li id="_2585"><a href="2585.htm" title="ENALAPRIL MALEATE">ENALAPRIL MALEATE</a></li><li id="_2589"><a href="2589.htm" title="FOSINOPRIL SODIUM">FOSINOPRIL SODIUM</a></li><li id="_77308"><a href="77308.htm" title="IMIDAPRIL HYDROCHLORIDE">IMIDAPRIL HYDROCHLORIDE</a></li><li id="_2591"><a href="2591.htm" title="LISINOPRIL">LISINOPRIL</a></li><li id="_37817"><a href="37817.htm" title="MOEXIPRIL HYDROCHLORIDE">MOEXIPRIL HYDROCHLORIDE</a></li><li id="_2597"><a href="2597.htm" title="PERINDOPRIL ERBUMINE">PERINDOPRIL ERBUMINE</a></li><li id="_207474"><a href="207474.htm" title="PERINDOPRIL ARGININE">PERINDOPRIL ARGININE</a></li><li id="_2599"><a href="2599.htm" title="QUINAPRIL">QUINAPRIL</a></li><li id="_2603"><a href="2603.htm" title="RAMIPRIL">RAMIPRIL</a></li><li id="_200392"><a href="200392.htm" title="RAMIPRIL WITH FELODIPINE">RAMIPRIL WITH FELODIPINE</a></li><li id="_2605"><a href="2605.htm" title="TRANDOLAPRIL">TRANDOLAPRIL</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="119651.htm">Previous: Heart failure</a> | <a class="top" href="2578.htm#">Top</a> | <a accesskey="]" href="2579.htm">Next: CAPTOPRIL</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>